Amarin Announces Results from Exploratory Phase 2a Study of EN101 in – Businesswire.com
In Acid Reflux | On June 13th, 2009 | By thearguyAmarin Announces Results from Exploratory Phase 2a Study of EN101 in – Businesswire.com
DUBLIN–( BUSINESS WIRE )–Amarin Corporation plc (NASDAQ:AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic
Related posts:
- Ception Therapeutics Initiates Phase II/III Clinical Trial for Its – PR Newswire
- New Study Spurs Concern About Chemical in IV Bags – Wall Street Journal
- Sequenom Announces New Positive Data on Down Syndrome Detection and – PR Inside
- DiaMedica Cleared to Initiate Its Second Phase II Clinical Trial … – MSNBC
- AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium) – News-Medical.Net
- Additional Phase II Data Demonstrate Improvement In Reported Symptoms – Medical News Today


You must be logged in to post a comment.